EU Actions ‘Will Weaken IP And Undermine Innovation’
PhRMA Attacks Commission’s Pharmaceutical Strategy
In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.
